Comparative outcomes highlight similar mortality in infections, indicating resistance patterns differ between treatments.
Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam. Emergence of resistance was higher in the ceftazidime-avibactam group (12% vs 0%); putative resistance mechanisms included porin mutations (Klebsiella pneumoniae) and R2 loop structural changes in AmpC (Enterobacter cloacae complex).
No takes yet. Share an insight, caveat, or question.
Karaba et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: